Ravindra Prasad Thokala: When T Cells Heal and Harm in the Same Transplant Unit
Ravindra Prasad Thokala, Transfusion Medicine Consultant and Head at Apollo Cancer Center, shared a post on LinkedIn:
“Two patients, two cell therapies, two opposite ends of the same immune system — and a striking reminder of why this cellular therapy is equal parts thrilling and humbling.
The first: adenovirus-specific T cells (CD4 and CD8) at a 5 million cell dose, prepared against refractory adenoviremia after a stem cell transplant, when the patient’s own reconstituting immunity and neither the list of antivirals simply cannot control the virus.
With turnaround — under 36 hours from leukapheresis to infusion (helped by Cytocare technologies for such a processing in the shortest time) — because in this race that speed can be the difference between staying ahead of the virus and forever chasing it.
The second: extracorporeal photopheresis for aggressive (fiery) acute skin GvHD, where the problem is the exact opposite — donor T cells that have turned on the patient’s own tissue, leaving the skin you see here.
Rather than simply suppressing those cells, photopheresis collects, treats and returns them in a way that tames the T cells gone rogue , same time gently retrains the immune response.
One therapy adds T cells to deliver might Against a virus; the other tames T cells that target the host — same cells, opposite missions, one shared goal of carrying a transplant patient safely through.
This is the reality of cellular therapy:
You would never wish either situation on a patient, but working in this space … you will eventually meet both.
Grateful to a team that can pivot between building immunity and calming it, sometimes on the very same day — and now we wait, watch and hope for both responses.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments